Targeted agents for the systemic treatment of advanced hepatocellular carcinoma |
| |
Authors: | Arun AZAD Fiona CHIONH Jonathan CEBON |
| |
Institution: | Department of Medical Oncology and;Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia |
| |
Abstract: | The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian–Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma. |
| |
Keywords: | angiogenesis inhibitor hepatocellular carcinoma receptor vascular endothelial growth factor SHARP sorafenib |
|